AUS1 Antibody

What is the AU1 epitope tag and what is its origin?

The AU1 tag is a short six-peptide epitope with the amino acid sequence DTYRYI. This sequence is derived from the major capsid protein of bovine papillomavirus-1 (BPV-1) . The tag is typically attached to either the N- or C-terminus of recombinant proteins to facilitate their detection and analysis in various experimental systems. The small size of this tag (just six amino acids) makes it particularly useful when minimal interference with protein function is desired.

What applications are AU1 tag antibodies suitable for?

AU1 tag antibodies have demonstrated utility across multiple immunological applications:

These applications make AU1 antibodies versatile tools for studying protein expression, localization, interaction, and quantification in research settings.

How should AU1 antibodies be stored to maintain optimal activity?

For optimal preservation of antibody activity, AU1 antibodies should be stored at 2-8°C, where they remain stable for at least one year . It's important to avoid repeated freeze-thaw cycles, as these can lead to protein denaturation and loss of binding activity. When handling the antibody, always work in clean conditions to prevent microbial contamination. The storage buffer (typically PBS with 0.09% sodium azide at pH 7.2) helps maintain antibody stability and prevents microbial growth during storage .

What is the difference between polyclonal and monoclonal AU1 antibodies?

The search results indicate that commercially available AU1 antibodies are primarily polyclonal in nature, available from either goat or rabbit hosts . Polyclonal antibodies offer several advantages:

This is in contrast to monoclonal antibodies which would recognize a single epitope within the AU1 tag sequence. For most research applications, polyclonal AU1 antibodies provide reliable detection with strong signal amplification.

How can I optimize western blot protocols when using AU1 antibodies?

Optimizing western blot protocols for AU1 antibody detection requires careful consideration of several parameters:

• Sample preparation: Ensure complete lysis and denaturation of samples using appropriate buffers containing protease inhibitors to prevent degradation of tagged proteins.

• Blocking optimization: Test different blocking agents (BSA, non-fat milk, commercial blockers) to determine which provides optimal signal-to-noise ratio. Generally, 5% non-fat milk in TBST provides good results, but protein-specific optimizations may be necessary.

• Antibody dilution: Begin with the manufacturer's recommended dilution range (1:1,000-1:20,000) and perform a dilution series to identify optimal concentration. For highly expressed proteins, higher dilutions (1:10,000-1:20,000) may provide cleaner results while conserving antibody.

• Incubation conditions: Overnight incubation at 4°C often provides improved signal compared to shorter room temperature incubations, especially for lower abundance proteins.

• Detection system selection: Choose between chemiluminescence (most sensitive), fluorescence (quantitative, multiplex capable), or colorimetric (economical, stable) based on your specific requirements. The experimental data indicates chemiluminescence can detect AU1-tagged proteins with exposure times as short as 3 seconds .

A systematic optimization approach testing these variables will yield the most reliable and consistent results for your specific AU1-tagged protein.

What strategies can address cross-reactivity or high background issues with AU1 antibodies?

When experiencing cross-reactivity or high background with AU1 antibodies, consider implementing these troubleshooting strategies:

• Increase antibody dilution: Using more dilute antibody solutions (within the recommended 1:1,000-1:20,000 range) can reduce non-specific binding .

• Modify blocking conditions: Test different blocking agents and concentrations. If using milk, consider switching to BSA or commercial blockers which may provide cleaner results for certain applications.

• Add detergent: Increasing Tween-20 concentration in wash buffers (up to 0.1%) can help reduce hydrophobic non-specific interactions.

• Pre-adsorption: For tissues or cells with endogenous proteins that may cross-react, pre-adsorption of the antibody with non-tagged lysates may reduce background.

• Control experiments: Always include negative controls (cells/lysates without the AU1-tagged protein) to distinguish true signal from background.

• Alternative detection systems: If chemiluminescence produces high background, consider fluorescence-based detection which may offer clearer distinction between specific and non-specific signals.

• Additional washes: Extending wash steps or increasing wash buffer volume can significantly reduce background without compromising specific signal.

These approaches can be implemented systematically to identify the optimal conditions for your specific experimental system.

How can I validate the specificity of AU1 antibody binding in my experimental system?

Validating antibody specificity is critical for generating reliable scientific data. For AU1 antibodies, implement these validation approaches:

• Negative controls: Include samples lacking the AU1-tagged protein to confirm absence of signal in these lanes/samples.

• Positive controls: Use a well-characterized AU1-tagged protein with known expression pattern and molecular weight as a reference.

• Epitope competition: Pre-incubate the antibody with excess synthetic AU1 peptide (DTYRYI) before application to your samples. Specific binding should be significantly reduced or eliminated.

• Molecular weight verification: Confirm that detected bands match the expected molecular weight of your AU1-tagged protein.

• Multiple detection methods: Validate findings using orthogonal techniques (e.g., if detected by western blot, confirm with immunofluorescence or immunoprecipitation).

• Titration experiments: Demonstrate that signal intensity correlates with the amount of AU1-tagged protein. The research data shows detection sensitivity across a range of concentrations (50-200 ng of tagged protein) .

• Genetic validation: If possible, use gene editing to remove the AU1 tag and demonstrate loss of antibody binding.

These validation steps provide strong evidence for antibody specificity and generate confidence in experimental results.

What considerations should guide the positioning of the AU1 tag within my protein of interest?

Strategic positioning of the AU1 tag requires balancing detection efficiency with preservation of protein function:

• Terminal tagging: N- or C-terminal positioning is most common and least likely to disrupt protein folding or function. Consider:

  • N-terminal placement if C-terminus is critical for function

  • C-terminal placement if N-terminus contains signal peptides or functional domains

• Structural considerations: Review available structural data to avoid disrupting:

  • Catalytic sites

  • Binding interfaces

  • Transmembrane domains

  • Post-translational modification sites

• Linker incorporation: Include flexible linkers (e.g., Gly-Ser repeats) between the tag and protein to minimize steric hindrance.

• Accessibility analysis: Ensure the tag will be accessible to antibodies in your application. Surface-exposed regions are preferable.

• Multiple constructs: Generate both N- and C-terminally tagged versions to identify optimal positioning empirically.

• Functional validation: Always confirm that the tagged protein retains wild-type activity through appropriate functional assays.

The small size of the AU1 tag (DTYRYI) provides an advantage over larger tags like GFP, reducing the likelihood of functional interference .

How can I quantitatively analyze AU1-tagged proteins in complex biological samples?

Quantitative analysis of AU1-tagged proteins can be accomplished through several methodological approaches:

• Quantitative western blotting:

  • Use fluorescent secondary antibodies rather than chemiluminescence

  • Include a standard curve of purified AU1-tagged protein

  • Employ image analysis software that accounts for linear dynamic range

  • Normalize to appropriate loading controls

• ELISA-based quantification:

  • Develop a sandwich ELISA using AU1 antibody (1:100-1:500 dilution) as capture

  • Use protein-specific antibody for detection

  • Generate standard curves with purified protein

  • Interpolate unknown samples

• Mass spectrometry integration:

  • Use immunoprecipitation with AU1 antibody (1-4 μg/mg lysate) to enrich tagged proteins

  • Add isotope-labeled reference peptides

  • Perform LC-MS/MS analysis

  • Quantify based on peptide intensity ratios

• Flow cytometry:

  • For cellular proteins, fix and permeabilize cells as needed

  • Label with AU1 antibody at appropriate dilution

  • Use fluorophore-conjugated secondary antibody

  • Quantify mean fluorescence intensity

Each method offers distinct advantages, with ELISA providing highest sensitivity, western blotting offering visual confirmation of molecular weight, mass spectrometry enabling multiplexed analysis, and flow cytometry allowing single-cell quantification.

What is the recommended protocol for immunoprecipitation of AU1-tagged proteins?

For optimal immunoprecipitation of AU1-tagged proteins, follow this methodological approach:

• Sample preparation:

  • Lyse cells in non-denaturing buffer (e.g., 150 mM NaCl, 50 mM Tris-HCl pH 7.4, 1% NP-40) with protease/phosphatase inhibitors

  • Clear lysate by centrifugation (14,000 × g, 10 min, 4°C)

  • Determine protein concentration

• Pre-clearing (optional but recommended):

  • Incubate lysate with protein A/G beads (25 μl per mg protein) for 1 hour at 4°C

  • Remove beads by centrifugation

• Immunoprecipitation:

  • Add AU1 antibody at 1-4 μg per mg of total protein

  • Incubate with rotation overnight at 4°C

  • Add 30 μl protein A beads (for rabbit antibody) or protein G beads (for goat antibody)

  • Incubate 2-3 hours at 4°C with rotation

• Washing:

  • Pellet beads at 1,000 × g for 1 minute

  • Wash 4-5 times with 1 ml cold lysis buffer

  • For final wash, use buffer without detergent

• Elution options:

  • Denaturing: Add SDS sample buffer and heat at 95°C for 5 minutes

  • Native: Elute with excess AU1 peptide (DTYRYI, 0.5-1 mg/ml)

• Analysis:

  • Proceed with western blotting or mass spectrometry

This protocol maximizes specific recovery while minimizing non-specific binding, ensuring high-quality immunoprecipitation results.

How does the AU1 tag system compare with other epitope tagging systems?

The AU1 epitope tag offers distinct advantages and limitations compared to other common tagging systems:

The AU1 tag is particularly valuable when minimal structural interference is required, making it suitable for functional studies of enzymes, membrane proteins, and proteins with critical terminal domains . Its small size (6 amino acids) provides a significant advantage over larger tags like GFP or GST, which can substantially alter protein behavior.

Can AU1 antibodies be used effectively in multiplex immunostaining applications?

AU1 antibodies can be effectively integrated into multiplex immunostaining protocols with careful consideration of these methodological aspects:

• Antibody compatibility:

  • Ensure primary antibodies are from different host species (e.g., rabbit anti-AU1 and mouse anti-other target)

  • Alternatively, use directly conjugated AU1 antibodies to eliminate species cross-reactivity

• Sequential staining protocol:

  • Apply first primary antibody (e.g., AU1 at 1:100-1:400 dilution)

  • Detect with fluorophore-conjugated secondary antibody

  • Block remaining secondary antibody binding sites

  • Apply second primary and corresponding secondary antibody

  • Include appropriate controls for cross-reactivity

• Spectral separation:

  • Select fluorophores with minimal spectral overlap

  • Consider brightness hierarchy (assign brightest fluorophores to least abundant targets)

  • Use spectral imaging and unmixing for closely overlapping signals

• Validation controls:

  • Single-stain controls to establish signal specificity

  • FMO (fluorescence minus one) controls to confirm lack of bleed-through

  • Absorption controls to verify blocking of species cross-reactivity

• Optimization steps:

  • Titrate AU1 antibody concentration to minimize background

  • Test fixation protocols for preservation of both AU1 epitope and other targets

  • Optimize antigen retrieval if necessary

When properly implemented, these approaches enable reliable multiplex detection of AU1-tagged proteins alongside other cellular markers.

What approaches can be used to study protein-protein interactions involving AU1-tagged proteins?

Multiple methodological approaches can be employed to investigate protein-protein interactions involving AU1-tagged proteins:

• Co-immunoprecipitation (Co-IP):

  • Immunoprecipitate AU1-tagged protein using AU1 antibody (1-4 μg/mg lysate)

  • Analyze precipitates by western blot for co-precipitating partners

  • Consider crosslinking for transient interactions

  • Include appropriate controls (non-tagged bait, IgG control)

• Proximity labeling:

  • Fuse AU1-tagged protein with BioID or APEX2

  • Express in cells and activate labeling

  • Purify biotinylated proteins using streptavidin

  • Identify partners by mass spectrometry

• Fluorescence microscopy:

  • Perform immunofluorescence using AU1 antibody (1:100-1:400) and antibodies against potential partners

  • Analyze co-localization using confocal microscopy

  • Consider super-resolution techniques for detailed spatial analysis

  • Quantify co-localization using appropriate statistical methods

• Fluorescence resonance energy transfer (FRET):

  • Tag interaction partner with fluorescent protein

  • Detect AU1-tagged protein with fluorophore-conjugated secondary antibody

  • Measure energy transfer as evidence of close proximity

  • Include appropriate controls for non-specific FRET

• Bimolecular fluorescence complementation (BiFC):

  • Fuse AU1-tagged protein with one half of split fluorescent protein

  • Fuse potential partner with complementary half

  • Analyze reconstituted fluorescence as indicator of interaction

• Pull-down assays:

  • Express and purify AU1-tagged protein

  • Immobilize on beads using AU1 antibody

  • Incubate with cell lysates or purified potential partners

  • Analyze bound proteins by western blot or mass spectrometry

These approaches provide complementary information about protein interactions, from binary binding to complex formation in native cellular environments.

What are effective strategies for detecting low-abundance AU1-tagged proteins?

Detecting low-abundance AU1-tagged proteins requires implementing sensitivity-enhancing strategies:

• Signal amplification methods:

  • Use high-sensitivity chemiluminescent substrates (e.g., femto-level ECL)

  • Implement tyramide signal amplification (TSA) for immunohistochemistry

  • Consider biotin-streptavidin amplification systems

  • Use tertiary antibody layers for additional signal enhancement

• Sample enrichment approaches:

  • Perform immunoprecipitation with AU1 antibody before analysis

  • Use subcellular fractionation to concentrate compartment-specific proteins

  • Implement protein concentration methods (TCA precipitation, acetone precipitation)

• Detection system optimization:

  • For western blotting, use high-sensitivity films or longer CCD camera exposures

  • For microscopy, use high-NA objectives and sensitive cameras

  • Extend primary antibody incubation time (overnight at 4°C)

  • Optimize blocking to reduce background without compromising signal

• Antibody considerations:

  • Use the most sensitive antibody formulation (consider testing both rabbit and goat anti-AU1)

  • Ensure antibody concentration is optimized (may require lower dilution within 1:1,000-1:20,000 range)

  • Consider direct detection with labeled primary antibody to reduce background

• Technical modifications:

  • Increase protein loading when possible

  • Use gradient gels for better protein separation

  • Consider more sensitive detection methods (e.g., Nano-ELISA platforms)

These approaches can be combined to achieve detection of very low abundance AU1-tagged proteins while maintaining specificity.

How can I optimize fixation and permeabilization conditions for immunocytochemistry with AU1 antibodies?

Optimizing fixation and permeabilization for AU1 immunocytochemistry requires balancing epitope preservation with cellular architecture:

• Fixation optimization:

  Fixative	Advantages	Considerations	Recommended Protocol
  4% Paraformaldehyde	Preserves structure, compatible with most epitopes	Can reduce accessibility	10-15 min at RT
  Methanol	Good for cytoskeletal proteins, increased permeability	Can denature some proteins	5-10 min at -20°C
  Acetone	Rapid fixation, good permeabilization	Can extract lipids	5 min at -20°C
  Glyoxal	Reduced autofluorescence, good morphology	Less common	20 min at RT
  PFA/Methanol (sequential)	Combines benefits of both	Multi-step process	10 min PFA, then 5 min methanol

• Permeabilization strategies:

  • Triton X-100 (0.1-0.5%): Effective for nuclear proteins, 5-15 minutes

  • Saponin (0.1-0.2%): Gentler, reversible, good for membrane proteins

  • Digitonin (10-50 μg/ml): Selective permeabilization of plasma membrane

  • No permeabilization: For surface-expressed AU1-tagged proteins

• Antigen retrieval considerations:

  • Heat-mediated: Citrate buffer (pH 6.0), 95°C for 10-20 minutes

  • Enzymatic: Proteinase K (1-5 μg/ml) for 5-15 minutes

  • Try multiple methods to determine optimal approach

• Optimization protocol:

  • Test matrix of conditions with different fixation/permeabilization combinations

  • Assess signal intensity, background, and morphology preservation

  • Include positive control (known high-expressing AU1-tagged protein)

  • Use AU1 antibody at manufacturer's recommended dilution (1:100-1:400)

• Special considerations:

  • For membrane proteins: gentler fixation and minimal permeabilization

  • For nuclear proteins: stronger permeabilization may be required

  • For cytoskeletal proteins: methanol fixation often superior

These approaches can be systematically tested to identify optimal conditions for specific AU1-tagged proteins in different cellular compartments.

What factors should be considered when using AU1 antibodies in experiments involving different cell types or model organisms?

When applying AU1 antibodies across diverse experimental systems, consider these methodological adaptations:

• Cell type considerations:

  • Primary cells vs. cell lines: Primary cells often require gentler fixation/permeabilization

  • Suspension vs. adherent cells: Modify wash protocols accordingly

  • Tissue-specific autofluorescence: Implement quenching steps for high-autofluorescence tissues

  • Species variation: Although AU1 is not species-specific, cell type background may vary

• Model organism adaptations:

  • Yeast: Require specialized cell wall digestion (zymolyase/lyticase treatment)

  • C. elegans/Drosophila: Need cuticle permeabilization (freeze-crack methods)

  • Plants: Cell wall necessitates modified extraction (enzymatic digestion)

  • Mammals: Tissue-specific fixation protocols may be required

• Antibody penetration strategies:

  • For thick specimens: Extend incubation times (24-48 hours at 4°C)

  • Consider sectioning for uniform antibody access

  • Use specialized permeabilization for tissue-specific barriers

  • Include carrier proteins to reduce non-specific binding

• Background reduction approaches:

  • Species-matched normal serum blocking (5-10%)

  • Endogenous peroxidase quenching for IHC (3% H₂O₂)

  • Endogenous biotin blocking if using biotin-streptavidin systems

  • Autofluorescence quenching (Sudan Black B, TrueBlack, etc.)

• Protocol optimization strategy:

  • Start with established protocols for specific organism/tissue

  • Systematically modify one variable at a time

  • Use appropriate positive controls (transfected cells expressing AU1-tagged protein)

  • Consider using longer incubation times with more dilute antibody solutions

These considerations enable successful application of AU1 antibodies across diverse experimental systems while maintaining specificity and sensitivity.

How might AU1 tag systems be integrated with emerging single-cell analysis technologies?

Integration of AU1 tag systems with single-cell technologies presents several promising methodological approaches:

• Single-cell proteomics applications:

  • Mass cytometry (CyTOF): Conjugate AU1 antibodies with rare earth metals

  • Microfluidic proteomics: Capture AU1-tagged proteins in nanoliter chambers

  • Single-cell western blotting: Adapt AU1 detection to microwell-based separation

  • Proximity extension assays: Pair AU1 antibodies with DNA barcodes for digital counting

• Spatial biology integration:

  • Multiplex ion beam imaging (MIBI): Use metal-conjugated AU1 antibodies

  • Imaging mass cytometry: Simultaneous detection of AU1-tagged proteins with tissue context

  • Spatial transcriptomics correlation: Combine AU1 immunofluorescence with in situ RNA detection

  • Super-resolution nanoscopy: Localize AU1-tagged proteins at nanometer resolution

• Single-cell functional analysis:

  • Live-cell AU1 detection using cell-permeable antibody fragments

  • Microfluidic trapping arrays with immunofluorescence capability

  • Droplet-based single-cell assays with AU1 antibody detection

  • Force-spectroscopy combined with AU1 recognition for mechanical studies

• Technical considerations:

  • Signal amplification requirements at single-cell level

  • Antibody specificity becomes increasingly critical

  • Need for automation and high-throughput processing

  • Data integration challenges across multi-omic platforms

These emerging approaches would enable unprecedented insights into protein dynamics, localization, and function at single-cell resolution, providing new understanding of cellular heterogeneity in normal and disease states.

What are the critical considerations for adapting AU1 antibody-based detection to automated high-throughput screening platforms?

Adapting AU1 antibody detection for high-throughput screening requires addressing these critical methodological aspects:

• Assay miniaturization challenges:

  • Volume reduction (384/1536-well format) requires optimized antibody concentration

  • Lower cell numbers necessitate signal amplification strategies

  • Edge effects and evaporation must be controlled

  • Maintaining appropriate controls across large plate formats

• Automation compatibility requirements:

  • Stable antibody formulations resistant to mechanical stress

  • Optimized incubation times compatible with workstation scheduling

  • Robust detection methods with low well-to-well variability

  • Quality control metrics and automated flagging of outliers

• Detection system considerations:

  • Fluorescence vs. luminescence trade-offs for sensitivity/throughput

  • Fixed-endpoint vs. kinetic measurements

  • Multiplexing capabilities with other readouts

  • Image-based vs. plate reader detection strategies

• Protocol optimization approaches:

  • Reduce steps to minimize handling and variability

  • Optimize wash protocols for automated liquid handlers

  • Develop "mix-and-read" formats where possible

  • Implement positive and negative controls on every plate

• Data analysis and management:

  • Automated image analysis for morphological features

  • Statistical methods for hit identification

  • Machine learning for pattern recognition

  • Data storage and retrieval systems for large datasets

• Validation strategy:

  • Orthogonal confirmation of primary hits

  • Dose-response relationships for quantitative assessment

  • Counter-screens to eliminate false positives

  • Secondary assays for mechanism confirmation

These considerations enable robust implementation of AU1-based detection in high-throughput screening environments while maintaining data quality and reproducibility.

What novel applications might emerge from combining AU1 tag systems with genome editing technologies?

The integration of AU1 tag systems with genome editing technologies presents exciting methodological opportunities:

• Endogenous protein tagging applications:

  • CRISPR-Cas9 knock-in of AU1 tags at native loci

  • Homology-directed repair to introduce precise AU1 tags

  • Prime editing for scarless AU1 tag insertion

  • Base editing for minimal genetic modification

• Multiplexed tagging strategies:

  • Combinatorial epitope tagging of protein families

  • Differential tagging of protein isoforms

  • Cell-type specific AU1 tagging using Cre-Lox systems

  • Inducible/conditional AU1 tagging for temporal studies

• Functional genomics integration:

  • CRISPR activation/repression combined with AU1 reporting

  • AU1 tagging of chromatin regulators for epigenetic studies

  • CRISPR screens with AU1-based phenotypic readouts

  • Lineage tracing with heritable AU1-tagged proteins

• Technical innovations:

  • Development of split AU1 tags for protein-protein interaction studies

  • AU1 tag arrays for multiplexed detection

  • Integration with optogenetic or chemogenetic control systems

  • Combination with degron systems for temporal control

• Therapeutic and diagnostic applications:

  • Engineered cell therapies with trackable AU1-tagged proteins

  • Patient-derived organoids with AU1-tagged disease proteins

  • Precision medicine applications detecting variant-specific changes

  • AU1-tagged biomarkers for diagnostic development

These emerging applications represent the convergence of precise genome engineering with efficient protein detection systems, enabling unprecedented insights into protein function in physiological contexts.